Telbivudine eliminates mother-to-child HBV transfer in study

04/12/2012 | InternalMedicineNews.com (free registration)

Telbivudine therapy at 12 to 30 weeks' gestation prevented mother-to-infant hepatitis B transmission, compared with 9% transmission in the control group, in a study of 88 pregnant women with high viral loads and alanine aminotransferase levels. Researchers reported that 77% of women who took the drug had normal ALT levels one month after giving birth, compared with 49% in the control group.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care